1. Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.
- Author
-
Sirivichayakul, Chukiat, Barranco-Santana, Elizabeth A, Rivera, Inés Esquilín, Kilbury, Jennifer, Raanan, Marsha, Borkowski, Astrid, Papadimitriou, Athanasia, and Wallace, Derek
- Subjects
VACCINATION of children ,IMMUNE response ,DENGUE ,CLINICAL trial registries ,ANTIBODY titer ,RESEARCH ,VIRAL vaccines ,IMMUNOGLOBULINS ,VACCINES ,CLINICAL trials ,FLAVIVIRUSES ,RESEARCH methodology ,EVALUATION research ,COMBINED vaccines ,COMPARATIVE studies ,RANDOMIZED controlled trials ,RESEARCH funding ,VIRAL antibodies - Abstract
Background: We report long-term safety and immunogenicity of Takeda's tetravalent dengue vaccine candidate (TAK-003) in healthy children and adults living in dengue-endemic areas in Puerto Rico, Columbia, Singapore, and Thailand.Methods: In part 1 of this phase 2, randomized, placebo-controlled trial we sequentially enrolled 1.5-45 year olds (n = 148) into 4 age-descending groups, randomized 2:1 to receive 2 doses of TAK-003 or placebo 90 days apart. In part 2, 1-11 year olds (n = 212) were enrolled and randomized 3:1 to TAK-003 or placebo groups. We assessed neutralizing antibody titers for the 4 dengue serotypes (DENV) up to month 36 in part 1, and symptomatic dengue and serious adverse events (SAEs) up to month 36 in both parts.Results: At month 36, seropositivity rates were 97.3%, 98.7%, 88.0% and 56.0% for DENV-1, -2, -3 and -4, respectively. Seropositivity rates varied significantly for DENV-4 according to serostatus at baseline (89.5% in seropositives versus 21.6% in seronegatives). No vaccine-related SAEs were reported.Conclusions: The trial demonstrated persistence of neutralizing antibody titers against TAK-003 over 3 years in children and adults living in dengue-endemic countries, with limited contribution from natural infection. TAK-003 was well tolerated.Clinical Trials Registration: NCT01511250. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF